Insmed Incorporated

INSM

$42.25

+57.29% (1 year change)

Avg closing price

Price range

Market Cap

$3.78 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$42.5 Million

Total revenue in the last quarter.

Net Income

-$61.9 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

-$2.65

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-15.63x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$-54.1 Million

Earnings before interest expenses and taxes in the last quarter.

Employees

0

The number of full time employees.

Revenue & Earnings

Balance Sheet

Insmed Incorporated

News

Insmed "Unbreakable" by ROOF Studio

Insmed "Unbreakable" by ROOF Studio

The team at ROOF Studio in New York engage their talents for hyper-detailed worlds and characters to elevate this film designed to raise awareness of NTM Lung Disease for biopharmaceutical brand In...

Stash Stash, 13 days ago
Insmed to Present at the 39th Annual J.P. Morgan Healthcare Conference

Insmed to Present at the 39th Annual J.P. Morgan Healthcare Conference

BRIDGEWATER, N.J., Jan. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases...

PR Newswire PR Newswire, 22 days ago
Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease

Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease

/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare…

PR Newswire PR Newswire, 23 days ago